For example, liraglutide, a well-known long-acting GLP-1 analogue, has been shown to improve endothelial function and reduce lipid burden and inflammation [18,19,20,21], which all play critical roles in the pathogenesis of CAVD. Here, GLP1R is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.